Facets and determinants of quality of life in patients with recurrent high grade glioma

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 4, 2005, Pages 562-568

  Giovagnoli, A R ^a   Silvani, A ^a   Colombo, E ^a   Boiardi, A ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN TUMOR; CHRONIC DISEASE; COGNITION; CONTROLLED STUDY; DISEASE DURATION; FACTORIAL ANALYSIS; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL LIVING INDEX CANCER; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; MULTIMODALITY CANCER THERAPY; NAUSEA; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; SCORING SYSTEM; SELF EVALUATION; SOCIAL ISOLATION; TUMOR RECURRENCE; VISUAL ANALOG SCALE; WELLBEING;

ADULT; BIOPSY; BRAIN NEOPLASMS; COGNITION DISORDERS; DEPRESSION; FACTOR ANALYSIS, STATISTICAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE; QUESTIONNAIRES; SOCIAL ISOLATION;

EID: 16844382818     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.036186     Document Type: Article

References (45)

1. Calman KC. Quality of life in cancer patients - an hypothesis. J Med Ethics 1984;10:124-8.
2. Prados MD, Scott CB, Rotman M, et al. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for gliablastama multifarme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1998;40:653-9.
3. Sneed PK, Stauffer PR, McDermott MW, et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost + hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998;40:287-95.
4. Levin VA, Leobel SA, Gutin PH. Neoplasms of the central nervous system. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 5th ed. Philadelphia PA: Lippincott-Raven, 1997:2022-8.
5. Mackworth N, Fobair P, Prados MD. Quality of life self-reports from 200 brain tumor patients: comparison with Karnofsky performance scores. J Clin Oncol 1992;14:243-53.
6. Giovagnoli AR, Boiardi A. Cognitive impairment and quality of life in long-term survivors of malignant brain tumars. Ital J Neurol Ssi 1994;15:481-8.
7. Taphoorn MJB, Schiphorst AK, Snoek FJ, et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 1994;36:48-54.
8. Murray KJ, Nelson DF, Scott C, et al. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02, Int J Radiat Oncol Biol Phys 1995;31:453-9.
9. Giovagnoli AR, Tamburini M, Boiardi A. Quality of life in brain tumor patients. J Neurooncol 1996;30:71-80.
10. Weitzner MA, Meyers CA, Byrne K. Psychosocial functioning and quality of life in patients with primary brain tumors. J Neurosurg 1996;84:29-34.
11. Choucair AK, Scott C, Urtasun R, et al. Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14. Int J Radiat Oncol Biol Phys 1997;38:9-20.
12. Jason GW, Pajurkova EM, Taenzer PA, et al. Acute effects on neuropsychological function and quality of life by high-dose multiple daily fractionated radiotherapy for malignant astrocytomas: assessing the tolerability of a new radiotherapy regimen. Psychooncology 1997;6:151-7.
13. Newton HB, Malkin MG. Ethical issues in neuro-oncology. Semin Neurol 1997;17:219-26.
14. Osoba D, Aaronson NK, Muller M, et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 1997;31:263-87.
15. Giovagnoli AR. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumor. J Neurol Neurosurg Psychiatry 1999;67:358-63.
16. Weitzner MA. Psychosocial and neuropsychiatric aspects of patients with primary brain tumors. Cancer Invest 1999;17:285-91.
17. Shrieve DC, Gutin PH, Larson DA. Central nervous system toxic effects of radiotherapy. In: Berger MS, Wilson CB, eds. The gliomas. Philadelphia, PA: WB Sounders Company, 1999:737-40.
18. Meyers CA, Hess KR, Yung WK, et al. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000;18:646-50.
19. Osoba D, Brada M, Prados MD, et al. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neurooncology 2000;2:221-8.
20. Armstrong CL, Hunter JV, Ledakis GE, et al. Late cognitive and radiographic changes related to radiotherapy. Neurology 2002;59:40-8.
21. Pelletier G, Verhoef MJ, Khatri N, et al. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol 2002;57:41-9.
22. Brada M, Yung WKA, Osoba D. Symptom burden in patients (PTS) with recurrent high-grade gliomas [abstract]. Proceedings of the American Society of Clinical Oncology 1999;18:147a.
23. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-71.
24. Dinnes J, Cave C, Huang S, et al. A rapid and systematic review of the effectiveness of temozolamide for the treatment of recurrent malignant glioma. Br J Cancer 2002;86:501-5.
25. Salander P, Bergenheim T, Henriksson R. How was life after treatment of a malignant brain tumor? Soc Sci Med 2000;51:589-98.
26. Costain KC, Hewison J, Howes M. Comparison of a function-based model and a meaning-based model of quality of life in oncology: multidimensionality examined. Journal of Psychosocial Oncology 1993;11:17-35.
27. Salander P, Karlsson T, Bergenheim T, et al. Long-term memory deficits in patients with malignant gliomas. J Neurooncol 1995;25:227-38.
28. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: McLoad CM, ed. Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949:191-205.
29. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: the functional living index-cancer: development and validation. J Clin Oncol 1984;2:472-83.
30. Spielberger CD. Inventario per l'ansia di stato e di tratto. Manuale. Firenze: Organizzazioni Speciali, 1989.
31. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
32. Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist 1970;10:20-30.
33. Basso A, Capitani E, Laiacona M. Raven's coloured progressive matrices: normative data on 305 adult normal controls. Functional Neurology 1987;2:189-94.
34. Spinnler H, Tognoni G. Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 1987;6(suppl 8):47-50.
35. Lezak M. Neuropsychological assessment. New York: Oxford University Press, 1995.
36. Novelli G, Papagno C, Capitani E, et al. Tre test clinici di memoria verbale a lungo termine. Taratura su soggetti normali. Archivio di Psicologia Neurologia e Psichiatria 1986;47:278-96.
37. Brada M, Yung WK. Clinical trial end points in malignant glioma: need for effective trial design strategy. Semin Oncol 2000;27(suppl 6):11-19.
38. Weitzner MA, Meyers CA. Cognitive functioning and quality of life in malignant glioma patients. Psychooncology 1997;6:169-77.
39. Fox S, Lantz C. The brain tumour experience and quality of life: a qualitative study. J Neurosci Nurs 1998;30:245-52.
40. Salander P, Bergenheim T, Henriksson R. The creation of protection and hope in patients with malignant brain tumors. Soc Sci Med 1996;42:985-96.
41. Mueller PS, Plevak DJ, Rummans TA. Religious involvement, spirituality, and medicine: implications for clinical practice. Mayo Clin Proc 2001;76:1225-35.
42. Rajan B, Ross G, Lim C, et al. Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer 1994;12:1809-15.
43. Van Zomeren AH, Brouwer WH. Clinical neuropsychology of attention. Oxford: Oxford University Press, 1994.
44. Anderson SW, Damasio H, Tranel D. Neuropsychological impairments associated with lesions caused by tumor or stroke. Arch Neurol 1990;47:397-405.
45. Huang ME, Wartella JE, Kreutzer JS. Functional outcomes and quality of life in patients with brain tumours: a preliminary report. Arch Phys Med Rehabil 2001;82:1540-6.